Stroke:大型人口学研究--血清钾与脑卒中及其病死率具有相关性!

2017-10-10 shaosai MedSci原创

血钾减低与心脑血管病、高血压和糖尿病患者脑卒中具有相关性,然而,尚无对健康人群进行该类研究。本研究旨在验证血清钾水平与脑卒中及其病死率发生间的相关性,并将结果发表在Stroke上。

血钾减低与心脑血管病、高血压和糖尿病患者脑卒中具有相关性,然而,尚无对健康人群进行该类研究。本研究旨在验证血清钾水平与脑卒中及其病死率发生间的相关性,并将结果发表在Stroke上。共收集有血清钾水平及相关参数的21353例患者(男性占79%,平均年龄44岁)。对脑卒中和死亡随访分析时间分别为26.9年、29.3年。共有2016次脑卒中事件发生和死亡8709例。Cox回归分析经调整脑卒中风险因素(年龄、性别、身高、体重、收缩压、快速血糖水平、血清钠、吸烟情况、糖尿病史、冠心病史和高血压治疗史)后模型拟合优度较好。血清钾每升高1 mmol/L与脑卒中(HR为1.33;95% CI:1.17-1.52;P<0.0001)及其病死率(HR为1.20;95%CI:1.13-1.28;P<0.0001)均有独立线性相关。与中年人群(平均年龄46.5岁)相比,年轻人和老年人均具有显着性差异,同时与血清钠有交互效应。在高血压和非高血压患者中,该相关与缺血性脑卒中和颅内出血均为正性且显着相关。本研究表明,中年人群中血清钾与缺血性脑卒中、颅内出血及全因死亡具有线性相关。其与血清钠的交互作用表明

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837349, encodeId=8911183e349e4, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Sep 03 08:30:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984291, encodeId=3ac819842913b, content=<a href='/topic/show?id=d6b1894e1c8' target=_blank style='color:#2F92EE;'>#血清钾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89471, encryptionId=d6b1894e1c8, topicName=血清钾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Nov 25 05:30:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677406, encodeId=317916e74068f, content=<a href='/topic/show?id=0101e089022' target=_blank style='color:#2F92EE;'>#病死率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70890, encryptionId=0101e089022, topicName=病死率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4da27497284, createdName=soongzhihua, createdTime=Sun Nov 19 09:30:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252436, encodeId=a83725243640, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Oct 13 07:42:16 CST 2017, time=2017-10-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1837349, encodeId=8911183e349e4, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Sep 03 08:30:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984291, encodeId=3ac819842913b, content=<a href='/topic/show?id=d6b1894e1c8' target=_blank style='color:#2F92EE;'>#血清钾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89471, encryptionId=d6b1894e1c8, topicName=血清钾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Nov 25 05:30:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677406, encodeId=317916e74068f, content=<a href='/topic/show?id=0101e089022' target=_blank style='color:#2F92EE;'>#病死率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70890, encryptionId=0101e089022, topicName=病死率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4da27497284, createdName=soongzhihua, createdTime=Sun Nov 19 09:30:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252436, encodeId=a83725243640, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Oct 13 07:42:16 CST 2017, time=2017-10-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1837349, encodeId=8911183e349e4, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Sep 03 08:30:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984291, encodeId=3ac819842913b, content=<a href='/topic/show?id=d6b1894e1c8' target=_blank style='color:#2F92EE;'>#血清钾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89471, encryptionId=d6b1894e1c8, topicName=血清钾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Nov 25 05:30:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677406, encodeId=317916e74068f, content=<a href='/topic/show?id=0101e089022' target=_blank style='color:#2F92EE;'>#病死率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70890, encryptionId=0101e089022, topicName=病死率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4da27497284, createdName=soongzhihua, createdTime=Sun Nov 19 09:30:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252436, encodeId=a83725243640, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Oct 13 07:42:16 CST 2017, time=2017-10-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1837349, encodeId=8911183e349e4, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Sep 03 08:30:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984291, encodeId=3ac819842913b, content=<a href='/topic/show?id=d6b1894e1c8' target=_blank style='color:#2F92EE;'>#血清钾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89471, encryptionId=d6b1894e1c8, topicName=血清钾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Nov 25 05:30:00 CST 2017, time=2017-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677406, encodeId=317916e74068f, content=<a href='/topic/show?id=0101e089022' target=_blank style='color:#2F92EE;'>#病死率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70890, encryptionId=0101e089022, topicName=病死率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4da27497284, createdName=soongzhihua, createdTime=Sun Nov 19 09:30:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=252436, encodeId=a83725243640, content=学习了提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Fri Oct 13 07:42:16 CST 2017, time=2017-10-13, status=1, ipAttribution=)]
    2017-10-13 杨利洪

    学习了提高了

    0

相关资讯

钾结合剂ZS-9可降低高钾血症复发(HARMONIZE试验)

近日,ZS制药公司发布的钾结合剂硅酸锆复合物(ZS-9)III期试验初步研究结果显示,每日3种剂量(5g、10g、15g)的ZS-9均可降低高钾血症28天的复发率。 HARMONIZE试验纳入了258例与慢性肾脏病(CKD)、心力衰竭(HF)、糖尿病和/或阻断血管紧张素醛固酮系统(RAAS)药物有关的高钾血症患者。 该试验包括开放标签期和随机期,在开放标签阶段,高钾血症患者接受ZS-9每日10

Am J Kidney Dis:透析患者血清钾和短期临床预后的关系

更高的血清钾与住院、急诊就诊和死亡的短期风险增加有关。血清钾和住院的风险之间的相关性可以被一周中不同的工作日所调整,其与长透析间间期导致血清钾聚集引起的不良预后相一致。通过直接的干预措施是否可以改善这种风险需要进一步的研究。